9月25日，南模生物涨0.57%，成交额5400.51万元。两融数据显示，当日南模生物获融资买入额425.21 万元，融资偿还579.84万元，融资净买入-154.63万元。截至9月25日，南模生物融资融券余额合计1.05 亿元。 融资方面，南模生物当日融资买入425.21万元。当前融资余额1.05亿元，占流通市值的2.56%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，南模生物9月25日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，上海南方模式生物科技股份有限公司位于上海市浦东新区琥珀路63弄1号6层，成立日期2000 年9月20日，上市日期2021年12月28日，公司主营业务涉及从事基因修饰动物模型的研发、生产、销售 及相关技术服务。主营业务收入构成为：标准化模型48.34%，模型技术服务21.92%，模型繁育 19.50%，定制化模型9.34%，其他(补充)0.91%。 机构持仓方面，截止2025年6月30日，南模生物十大流通股东中，融通健康产业灵活配置混合A/B （0 ...

9月22日，南模生物涨5.71%，截至发稿，报57.24元/股，成交1223.08万元，换手率0.28%，总市值44.63 亿元。 资料显示，上海南方模式生物科技股份有限公司位于上海市浦东新区琥珀路63弄1号6层，成立日期2000 年9月20日，上市日期2021年12月28日，公司主营业务涉及从事基因修饰动物模型的研发、生产、销售 及相关技术服务。主营业务收入构成为：标准化模型48.34%，模型技术服务21.92%，模型繁育 19.50%，定制化模型9.34%，其他(补充)0.91%。 从南模生物十大流通股东角度 数据显示，融通基金旗下1只基金位居南模生物十大流通股东。融通健康产业灵活配置混合A/B （000727）二季度减持15万股，持有股数80万股，占流通股的比例为1.03%。根据测算，今日浮盈赚取 约247.2万元。 融通健康产业灵活配置混合A/B（000727）成立日期2014年12月25日，最新规模20.74亿。今年以来收益 20.36%，同类排名4289/8244；近一年收益44.25%，同类排名3678/8066；成立以来收益190.8%。 融通健康产业灵活配置混合A/B（000727）基金经理 ...

Core Viewpoint - Nanmo Biotechnology experienced an 8.34% increase in stock price on August 27, with a trading volume of 250 million yuan, indicating strong market interest and activity [1]. Financing Summary - On August 27, Nanmo Biotechnology had a financing buy-in amount of 24.30 million yuan, with a financing repayment of 27.23 million yuan, resulting in a net financing buy of -2.93 million yuan [1]. - As of August 27, the total financing and securities lending balance for Nanmo Biotechnology was 110 million yuan, which represents 2.28% of its circulating market value, indicating a high level of financing activity compared to the past year [1]. - The company had no shares sold or repaid in securities lending on August 27, with a securities lending balance of 0.00 yuan, also reflecting a high level compared to the past year [1]. Business Performance - As of March 31, the number of shareholders for Nanmo Biotechnology was 6,252, an increase of 1.72% from the previous period, while the average circulating shares per person decreased by 1.70% to 7,899 shares [2]. - For the first quarter of 2025, Nanmo Biotechnology reported a revenue of 88.40 million yuan, representing a year-on-year growth of 6.59%, while the net profit attributable to the parent company was -0.97 million yuan, showing a significant year-on-year increase of 92.50% [2]. Dividend and Shareholding Structure - Since its A-share listing, Nanmo Biotechnology has distributed a total of 30.04 million yuan in dividends, with 10.00 million yuan distributed over the past three years [3]. - As of March 31, 2025, among the top ten circulating shareholders, the "Rongtong Health Industry Flexible Allocation Mixed A/B" fund held 950,000 shares, a decrease of 200,000 shares from the previous period, while "Zhaoshang Quantitative Selected Stocks Initiated A" and "Jiaoyin Medical Innovation Stocks A" were newly added shareholders with holdings of 384,300 shares and 374,900 shares, respectively [3].